Evaluation of the PhageTech Virus BioResistor

PhageTech, Inc.50 enrolled

Overview

To evaluate the effectiveness of the PhageTech Virus BioResistor to detect bladder cancer biomarkers.

This study will sample urine provided by bladder cancer patients as part of their normal routine surveillance screening. No additional effort will be required from the patients and only modest additional effort from the study staff. Some de-identified patient medical information may also be requested, including concominant medications, relevant current or previous diseases, prior bladder cancer interventions and other relevant information to ensure there are no interfering substances or other confounders that could affect study results. There is no risk to patients as the normal diagnostics for bladder cancer will be followed.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Bladder Cancer

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male and female patients ≥ 18 years 2. Previous bladder cancer diagnosis; any stage and histological type, undergoing cystoscopy 3. Patients with suspected bladder tumor undergoing surveillance cystoscopy 4. Patients must provide written Informed Consent. Exclusion Criteria: 1. Patients unable or unwilling to sign the informed consent 2. Age \< 18 years 3. Known HIV/HCV/HBV (information from clinical history).

Locations (1)

Providence Saint John's Health Center and the Saint John's Cancer Institute

Santa Monica, California, United States

RECRUITING

Outcomes

Primary Outcomes

Successful identification of bladder tumor biomarkersBiomarkers in Patients Under Active BCa Surveillance

Time frame: Up to 1 year

Central Contacts

Rodney Brenneman

CONTACT

949-433-6007 rbrenneman@phagetech.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.